BR112012023421A2 - composição farmacêutica para tratamento de aumento de pressão intraocular - Google Patents

composição farmacêutica para tratamento de aumento de pressão intraocular

Info

Publication number
BR112012023421A2
BR112012023421A2 BR112012023421A BR112012023421A BR112012023421A2 BR 112012023421 A2 BR112012023421 A2 BR 112012023421A2 BR 112012023421 A BR112012023421 A BR 112012023421A BR 112012023421 A BR112012023421 A BR 112012023421A BR 112012023421 A2 BR112012023421 A2 BR 112012023421A2
Authority
BR
Brazil
Prior art keywords
pressure increase
intraocular pressure
pharmaceutical composition
compositions
increase treatment
Prior art date
Application number
BR112012023421A
Other languages
English (en)
Other versions
BR112012023421B1 (pt
Inventor
Bastian Theisinger
Bernhard Günther
Sonja Theisinger
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of BR112012023421A2 publication Critical patent/BR112012023421A2/pt
Publication of BR112012023421B1 publication Critical patent/BR112012023421B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica para tratamento de aumente de pressão intraocular. a invenção fornece novas composições farmacêuticas para o tratamento de aumento de pressão intraocular baseada em alcanos semifluorinados que são úteis como veículos para uma ampla faixa de ingredientes ativos. ingredientes ativos preferidos incluem análogos de prostaglandina poucos solúveis em água. as composições podem ser administradas topicamente no olho. a invenção ainda fornece kits compreendendo tais composições.
BR112012023421-8A 2010-03-17 2011-03-16 Composição farmacêutica para tratamento de aumento de pressão intraocular BR112012023421B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10002800.0 2010-03-17
EP10002800 2010-03-17
PCT/EP2011/053949 WO2011113855A2 (en) 2010-03-17 2011-03-16 Pharmaceutical composition for treatment of increased intraocular pressure

Publications (2)

Publication Number Publication Date
BR112012023421A2 true BR112012023421A2 (pt) 2016-06-07
BR112012023421B1 BR112012023421B1 (pt) 2021-09-14

Family

ID=42223897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023421-8A BR112012023421B1 (pt) 2010-03-17 2011-03-16 Composição farmacêutica para tratamento de aumento de pressão intraocular

Country Status (15)

Country Link
US (4) US10045996B2 (pt)
EP (1) EP2547323B1 (pt)
JP (1) JP5816636B2 (pt)
KR (1) KR101656121B1 (pt)
CN (1) CN102869345B (pt)
AU (1) AU2011229235B2 (pt)
BR (1) BR112012023421B1 (pt)
CA (1) CA2788060C (pt)
DK (1) DK2547323T3 (pt)
ES (1) ES2564502T3 (pt)
HK (1) HK1175398A1 (pt)
IN (1) IN2012DN06581A (pt)
MX (1) MX2012010684A (pt)
PL (1) PL2547323T3 (pt)
WO (1) WO2011113855A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
AU2012260787B2 (en) 2011-05-25 2017-02-02 Dermaliq Therapeutics, Inc. Topical pharmaceutical composition based on semifluorinated alkanes
EP2806886B1 (en) 2012-01-23 2017-03-01 Novaliq GmbH Stabilised protein compositions based on semifluorinated alkanes
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US20150174096A1 (en) 2012-06-12 2015-06-25 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
DK2708228T3 (en) * 2012-09-12 2018-08-20 Novaliq Gmbh COMPOSITION FOR EYE RINSE
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CN104755073B (zh) 2012-09-12 2017-12-26 诺瓦利克有限责任公司 半氟化烷烃组合物
EP2783703A1 (en) * 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
WO2015134510A1 (en) 2014-03-03 2015-09-11 Encore Vision Inc. Lipoic acid choline ester compositions and methods of use
CN104606173A (zh) * 2014-12-26 2015-05-13 上海杰视医疗科技有限公司 一种含氟烷烃的用途
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
WO2019005139A1 (en) * 2017-06-30 2019-01-03 Jenivision Inc. FORMULATIONS FOR HAIR GROWTH
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CN110248657A (zh) * 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
BR112019021917A8 (pt) 2017-04-21 2023-03-21 Novaliq Gmbh Composições de iodo
WO2018202835A1 (en) 2017-05-05 2018-11-08 Novaliq Gmbh Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
BR112020006072A2 (pt) * 2017-09-27 2020-10-06 Novaliq Gmbh composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US20210228595A1 (en) * 2018-04-27 2021-07-29 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
WO2019213330A1 (en) * 2018-05-01 2019-11-07 Idrop, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2021247208A1 (en) * 2020-06-01 2021-12-09 Ads Therapeutics Llc Topical ophthalmological compositions and methods for treating abnormal angiogenesis

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US6184250B1 (en) * 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (pt) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
DK1105096T3 (da) 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
NZ513441A (en) 1999-02-08 2004-01-30 Alza Corp Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) * 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
CZ301310B6 (cs) 2001-09-04 2010-01-13 Trommsdorff Gmbh & Co. Kg Arzneimittel Náplast
AU2002325220A1 (en) 2002-05-24 2003-12-12 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP2007503428A (ja) 2003-08-25 2007-02-22 フォーミックス エルティーディー． 浸透性医薬発泡剤
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
AU2004293027A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
CA2563544A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
US20050288197A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer topical eye compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
RU2007103835A (ru) 2004-07-01 2008-08-10 Шепенс Ай Рисерч (Us) Композиции и способы лечения заболеваний и нарушений состояния глаз
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
AU2006310113A1 (en) 2005-08-05 2007-05-10 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070238732A1 (en) 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008060359A2 (en) 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
CN101553406B (zh) 2006-12-07 2011-05-04 太阳医药高级研发有限公司 用于施加微升量的液滴形式的液体的可计量的滴瓶
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
ITMI20070890A1 (it) 2007-05-04 2008-11-05 Sifi Spa Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
PT2110126E (pt) 2008-04-18 2012-02-20 Novaliq Gmbh Utilização inalativa e instilativa de alcanos semifluorados como veículos de substância activa na região intrapulmonar
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
CA2743824A1 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
CN102802619A (zh) 2009-06-25 2012-11-28 狮王株式会社 眼科用组合物
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
PT2387391T (pt) 2009-07-24 2017-04-20 Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
JP6073244B2 (ja) 2011-01-04 2017-02-01 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
AU2012260787B2 (en) 2011-05-25 2017-02-02 Dermaliq Therapeutics, Inc. Topical pharmaceutical composition based on semifluorinated alkanes
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP2806886B1 (en) 2012-01-23 2017-03-01 Novaliq GmbH Stabilised protein compositions based on semifluorinated alkanes
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CN104755073B (zh) 2012-09-12 2017-12-26 诺瓦利克有限责任公司 半氟化烷烃组合物
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2015153469A1 (en) 2014-03-31 2015-10-08 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
WO2016025560A1 (en) 2014-08-13 2016-02-18 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
WO2016082644A1 (en) 2014-11-26 2016-06-02 The University Of Hong Kong A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
WO2016108130A1 (en) 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
EP3463344A4 (en) 2016-06-01 2020-02-12 Harold Richard Hellstrom TREATMENT OF DRY EYE WITH PARASYMPATHIC AND ANTISYMPATHIC AGENTS
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CA3036313A1 (en) 2016-09-28 2018-04-05 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CN110248657A (zh) 2016-12-22 2019-09-17 诺瓦利克有限责任公司 用于治疗眼内炎性眼病的包含他克莫司的组合物
ES2965883T3 (es) 2016-12-23 2024-04-17 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco

Also Published As

Publication number Publication date
KR20130016280A (ko) 2013-02-14
US10555953B2 (en) 2020-02-11
US20190240234A1 (en) 2019-08-08
AU2011229235B2 (en) 2014-08-14
CN102869345B (zh) 2015-02-11
CN102869345A (zh) 2013-01-09
IN2012DN06581A (pt) 2015-10-23
BR112012023421B1 (pt) 2021-09-14
US20200206241A1 (en) 2020-07-02
HK1175398A1 (en) 2013-07-05
US10045996B2 (en) 2018-08-14
EP2547323A2 (en) 2013-01-23
DK2547323T3 (en) 2016-05-02
JP5816636B2 (ja) 2015-11-18
KR101656121B1 (ko) 2016-09-08
EP2547323B1 (en) 2016-01-27
US20130046014A1 (en) 2013-02-21
WO2011113855A2 (en) 2011-09-22
ES2564502T3 (es) 2016-03-23
JP2013522272A (ja) 2013-06-13
CA2788060C (en) 2017-07-11
US11324757B2 (en) 2022-05-10
WO2011113855A3 (en) 2011-11-17
MX2012010684A (es) 2012-11-06
CA2788060A1 (en) 2011-09-22
PL2547323T3 (pl) 2016-07-29
AU2011229235A1 (en) 2012-09-13
US20180303849A1 (en) 2018-10-25
US10525062B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
CL2017002650A1 (es) Compuestos novedosos
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
CO6341577A2 (es) Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
MA33939B1 (fr) 5-alcynyl-pyrimidines
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
MX338916B (es) Oxazepinas como moduladores del canal de iones.
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
NZ607580A (en) N-heteroaryl compounds
CO6660462A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.